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The U.S. pharmaceutical industry plays a vital role in shaping the face of American health-
care. As an industry rooted in innovation, its continued evolution is inherent. With major
patent expirations looming and thin product pipelines, the industry now must consider new
directions to maintain growth and stability. Follow-on biologics, derived from living organisms
and marketed after the patent expiration of similar therapies, represent a growing opportunity
for big pharmaceutical firms, as discussed during Yale’s Healthcare 2010 conference in
April. Key characteristics of follow-on biologics make them a worthwhile investment for big
pharma companies: They command high prices, will likely have fewer entrants than generics
due to high barriers to entry, and play to the existing strengths of big pharma firms. With the
recent healthcare legislation providing the way for consistent Food and DrugAdministration
(FDA†) regulation, the timing seems right to continue the push into this new and growing
market.
At a time when healthcare issues are
on the mind of every American, it would
serve us well to consider the future of one
of the most influential players in the sector:
pharmaceutical companies. National health
expenditures for pharmaceutical products
are hovering around 10 percent, meaning
that one out of every 10 dollars that we, as
a nation, spend on healthcare goes toward
drugs.These drugs regulate our cholesterol
levels, promote the growth of white blood
cells in cancer patients, manage our restless
leg syndrome, help us sleep better at night,
and provide myriad other benefits to our
health and well-being. Yet, for all the ben-
efits that the pharmaceutical industry pro-
vides, it is also criticized by many for the
expense of its products and the high profit
margins that these products command.The
growing popularity of biologics — treat-
ments derived from living organisms, such
as antibodies and interleukins — has par-
ticularly increased the price of drugs in the
United States. The current price of the av-
erage biologic is more than 20 times that of
a traditional, chemically synthesized small-
molecule drug.There is a trade-off between
high prices and innovative new therapies.
Moreover, pharmaceutical companies
themselves argue justifiably that prices ac-
To whom all correspondence should be addressed: Ian Evans, Graduate School of Arts &
Science, Genetics, Yale University, New Haven, CT; E-mail: ian.evans@yale.edu.
†Abbreviations: FDA, Food and Drug Administration; R&D, research and development;
TNF, tumor necrosis factor; EU, European Union, PPACA, Patient Protection and
Affordable Care Act.Evans: Follow-on biologics: a new play for big pharma 98
count not only for the price of production,
but also for the research and development
(R&D) for that therapy as well as numerous
others that did not make it all the way
through the regulatory process and to the
clinic.
In recent years, we have witnessed the
breakdown of the well-oiled innovation ma-
chinery of the traditional big pharma com-
pany. While R&D departments spent more
and more (well over $1B per drug), they did
not see promising results in the form of late-
stage drug candidates [1]. Over time, this led
to a strategic shift in portfolio management
within big pharma companies toward an ac-
quisition-heavy plan to build up their
pipeline of drugs. In-house R&D projects
were cut, and layoffs of scientific staff were
rampant. This phenomenon continues, with
2009 bearing witness to the most mergers
and acquisitions in the pharmaceutical in-
dustry to date. Industry-wide consolidation
aimed to find complementary development
projects and synergies in manufacturing and
emerging markets. What has been the effect
of all of this?The answer is not as hopeful as
the pharmaceutical industry would have
liked.Agiant “patent cliff” still persists, re-
ferring to a number of blockbuster drugs that
will go off patent over the next two years
and cause a dramatic decrease in sales for
big pharma firms. Without a strong pipeline
to fill in the valley with new product sales,
big pharma companies have begun scram-
bling to find new ways to generate revenue.
Meanwhile, the biotech industry’s foray
into therapeutics has been a wild success
story. From the 1980s to the present, biolog-
ics have reshaped the face of medicine in
many disease areas.The spawn of highly in-
novative, nimble biotech firms, biologic
drugs are large, complex molecules grown
in living cells rather than synthesized chem-
ically like small molecules. For example,
Enbrel is a fusion protein that acts as a tumor
necrosis factor (TNF) inhibitor to stop in-
flammation. This drug is being widely pre-
scribed for rheumatoid arthritis as well as
psoriasis, among other indications, with
sales last year reaching $5.9 billion, up 9.3
percent from 2008 [2]. Enbrel was first de-
veloped by Immunex and released in 1998.
Immunex was acquired by a rival biotech
firm, Amgen, in 2001 [3], and subsequent
marketing of the drug in the United States
was jointly undertaken by Amgen and
Wyeth (now taken over by Pfizer in the
mega-merger of 2009). Enbrel’s is the clas-
sic story of the modern biologic: a novel
therapy developed at a small biotech firm
and acquired or licensed up the food chain to
feed bigger firms’appetites for late-stage as-
sets.
Enbrel is by no means unique; there are
many blockbuster biologics on the market.
Like Enbrel, many of them will reach the
end of their patent life soon. Enbrel’s patent
expiration is set for 2012, at which time it
will be exposed to potential competition
from generic versions. Therefore, though
there are many novel biologics therapies that
can provide new ways of treating patients,
there is also a huge opportunity for generic
versions of biologics that did not exist even
one decade ago. This opportunity is hard to
quantify, but one recent estimate shows that
biologics responsible for $20B in annual
sales will go off patent by 2015 [4]. Unsur-
prisingly, small-molecule generics firms are
flocking to this space. Teva, the world’s
largest generics manufacturer, has partnered
with the Lonza Group to make and sell so-
called follow-on biologics.These treatments
are similar, but not identical, to preceding bi-
ologics whose patents expired. Meanwhile,
Novartis’s generics arm, Sandoz, has in-
creased capacity in biomanufacturing to
ramp up its efforts. Big pharma itself has
made motions of interest in the business of
follow-on biologics, as witnessed by the
dedicated division of Merck, BioVentures,
established in late 2008 for the development
of follow-on biologics. Interestingly, even
Pfizer is testing a follow-on version of En-
brel, now in phase 2 clinical trials [5]. With
a big market opportunity and a number of
firms interested, follow-on biologics will
surely play an important role in shaping the
future of the pharma industry.
For large pharmaceutical firms, what is
needed is a way to diversify and mitigate
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sales figures year after year. Follow-on bio-
logics may be a smart play for big pharma
companies. Like their generic cousins, bio-
logics manufacturing has strong economies
of scale that big pharma firms can leverage.
But unlike generics, there are higher barriers
to entry because of the technical challenges
of manufacturing biologics and the neces-
sary clinical proofs of equivalency. Pharma-
ceutical companies already are practiced at
navigating the global clinical-trials arena
and should be able to exercise a significant
competitive advantage in this area, espe-
cially over the existing generics manufactur-
ers attempting a play in the follow-on
biologics market. It has been estimated that
the investment necessary to bring a follow-
on biologic to market is eight to 10 years and
will cost $100-$200M [6]. This investment
of time and capital is substantial and tends to
favor larger firms with significant R&D
budgets. However, to put the investment into
perspective, this is only one-tenth of the cost
of developing a full-scale innovative phar-
maceutical product and has less associated
risk of failure — a proposition that the big
pharma industry should find appealing.Ad-
ditionally, the trend for current follow-on bi-
ologics on the market in the European Union
(EU) and United States has been to use tra-
ditional detailing and marketing practices to
compete with branded products. This, too,
puts big pharma at a competitive advantage
over other players lacking an army of detail-
ing pharmaceutical reps, who can use their
established relationships with doctors and
medical personnel to promote new follow-
on biologics.
One counter-argument to the case for a
move into follow-on biologics is that the
new healthcare reform, the Patient Protec-
tion and Affordable Care Act (PPACA),
passed in March of this year will harm any
would-be generic biologics makers with its
12-year exclusivity for branded biologics.
However, while this length of time is signif-
icantly longer than the proposed five years
that generics proponents pushed for, the
surety of a secure path forward through the
FDA for follow-on biologics outweighs the
downside of lengthy biologics exclusivity. It
is reasonable to hope that within two to three
years, the FDA will have functional guide-
lines for the regulation of this nascent mar-
ket. Now more than at any other time in the
past, the ambiguity associated with govern-
ment regulation is manageable. And if big
pharma becomes more intentional about en-
tering the follow-on biologics market, its
powerful lobby, PhRMA, could influence
the way that the details of the FDA regula-
tions are written.
If the pharma industry does find the fol-
low-on biologics market appealing and
makes a bet on it for supplementary revenue,
what can we expect from the patient per-
spective? It could mean greater access at
cheaper prices, but the dynamics are much
more nuanced. The economics of the small-
molecule generics market likely will not be
transferrable to the follow-on biologics mar-
ket. High barriers to entry, high fixed costs
of manufacturing, and marketing expenses
will more likely manifest themselves in a
market that has a small number of firms with
relatively small price drops upon introduc-
tion of follow-on therapies. In small-mole-
cule generics, the price typically decreases
by about 80 percent from the original
branded drug price after one year of generic
competition. However, in current follow-on
markets in the EU, this has not been the
case. Since its introduction of biosimilars
regulation in 2004, the EU has successfully
introduced numerous follow-on biologics
for three classes of branded drugs. The re-
sults hint at what might be expected for U.S.
firms: By 2008 in Germany, biosimilars had
captured an estimated 14 percent to 30 per-
cent market share and discounted prices by
25 percent [7]. The U.S. story of follow-on
biologics will likely mirror that of EU
biosimilars rather than that of small-mole-
cule generics.
With healthcare legislation passed and
the inevitable refocusing on bending the cost
curve in healthcare expenditures, big
pharma firms may be able to boost their rep-
utation with the public as well as their bot-
tom line with a continued push into
follow-on biologics. The decreased risk of
approval and steady returns will help diver-Evans: Follow-on biologics: a new play for big pharma 100
sify pharmaceutical companies’volatile rev-
enue streams, while concurrently winning
favorable public opinion by promoting price
reductions for some of the most expensive
drugs available. The cost savings to con-
sumers will increase access for patients as
FDA regulation is finalized and more and
more follow-on biologics enter the market.
This could be a win-win scenario for big
pharma and for patients.
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